HK Stock Market Move | HENLIUS (02696) rose by more than 8%. The company's drug, Hansilin, has won the exclusive indication globally.

HENLIUS (02696) rose by more than 8%, at the time of publication, it rose by 8.52% to HK$61.75, with a trading volume of HKD 42.2141 million. In terms of news, HENLIUS recently announced that its independently developed anti-PD-1 monoclonal antibody H drug HanSi Zhuang (seroluimab, European trade name: Hetronifly) has received formal approval from the National Medical Products Administration (NMPA) for its new drug application (NDA) through the priority review procedure. It is approved for use in combination with oxaliplatin and tegafur for neoadjuvant and adjuvant monotherapy of resectable gastric cancer with tumor PD-L1 expression CPS5. This NMPA approval makes H drug the world's first and only anti-PD-1 monoclonal antibody approved for perioperative therapy of gastric cancer, filling the clinical treatment gap in this area. In addition, this approach enables immunotherapy as a postoperative monotherapy instead of traditional adjuvant chemotherapy, significantly improving efficacy while effectively avoiding chemotherapy-related toxic side effects. Its commercial value and future growth potential are being reassessed, and it is expected to reshape the landscape of gastric cancer treatment.